RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes
- 25 April 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (17), 3434-3446
- https://doi.org/10.1182/blood-2012-06-434423
Abstract
Key Points BMI1 overexpression is one of the second hit partner genes of RUNX1 mutations that contribute to the development of MDSs.Keywords
This publication has 50 references indexed in Scilit:
- Familial myelodysplastic syndromes: a review of the literatureHaematologica, 2011
- RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosisBlood, 2011
- Transcription factor mutations in myelodysplastic/myeloproliferative neoplasmsHaematologica, 2010
- AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterationsBlood, 2009
- Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation statusBlood, 2009
- RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformationLeukemia, 2009
- Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemiaBlood, 2007
- Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemiaOncogene, 2004
- High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasiaBlood, 2004
- Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemiaNature Genetics, 1999